Redfaces, I think you are right. If the world takes on the...

Redfaces, I think you are right. If the world takes on the technology I don't think the numbers count for much. I'm not dismissing your imput Decan, but I think your analysis applies more to companies where the underlying value can be more accurately assessed. Remember equities try to estimate future value. The value of the options is pretty small anyway, so I take the point that they are not worth much (about $420,000) to the company. The really important question is whether this technology can assist the increasing numbers of people with asthmatic and other pulmonary complications. One statistic I am aware of is that pulmonary ailments are being diagnosed in increasing numbers throughout most of the 1st and 2nd world, so the potential customer base is expanding.